Eduardo Magalhães Rego

Eduardo Magalhães Rego

Professor of Hematology/Oncology, Medical School of Ribeirão Preto, University of São Paulo
Head of the Hematology and Clinical Oncology Service of the University Hospital (HC-FMRP)
Coordinator in Brazil of the International Consortium on Acute Leukemias which is sponsored by the American Society of Hematology
Member of the Board of Directors of the Brazilian Association of Hematology (ABHH)
Editor of the Brazilian Journal of Medical and Biological Research and Associate
Editor of Blood and Annals of Hematology

emrego@hcrp.fmrp.usp.br
PubMed Scopus ORCID  ResearcherID Scholar 

1983-1988 Doctor of Medicine (M.D.) Medical School of Ribeirão Preto of the University of São Paulo
1989-1992 Medical Residence/ Fellowship in Hematology, University Hospital, Medical School of Ribeirão Preto of the University of São Paulo
1993-1997 Doctor of Philosophy (Ph.D.) Medical School of Ribeirão Preto of the University of São Paulo
1998-2001 Post-Doctoral Fellowship Memorial Sloan-Kettering Cancer Center, New York, USA
2002 Full Professor, University of São Paulo, USP, Brazil
2005 PhD in Medicine, Fox Chase Cancer Center, FCCC, USA

Hematological malignancies, in particular acute leukemias
Leukemogenesis
Animal models of acute leukemia
Leukemia and cancer stem cells

BV-CDI FAPESP

The main focus of our group is to integrate basic and clinical research on acute leukemias, in special acute myeloid leukemias. In order to have a better insight on the molecular basis of leukemogenesis, we have been studying acute promyelocytic leukemia (APL) as a model. We have been addressing the following questions:

1. Which cell subpopulation acts the leukemia initiating cells and how is quiescence and energy generation regulated in this subset;

2. Which microRNAs act as key regulators of differentiation in APL blasts and whether their expression profile are associated with treatment outcome;

3. Does the expression of transcriptinally active and inactive isoforms of the p73 gene affect the response to ATRA and if so how?

4. What is the role of microparticles and annexin II expression in APL-associated coagulopathy;

5. Can the molecular monitoring of the PML/RARA fusion gene using RQ-PCR technology predict relapse better than the routinely used RT-PCR method?;

6. Is leukemia relapse is associated with additional mutagenic events?

7. In leukemia prone syndromes, such as dyskeratosis congenita, which pathways confer survival advantage to hematopoietic progenitors and are associated in malignant transformation. Finally, our group is coordinating in Brazil the International Consortium on APL, which is a trial aiming to improve the treatment outcome of APL patients in developing countries.

1. PhD students:
a. Ana Paula A. de L. Lange
b. Antonio R. L. de Araújo
c. Helder Henrique Paiva
d. Sarah Cristina Bassi
2. MsC students:
a. Katarina Holanda
3. Post-docs:
a. Priscila Santos Scheucher
b. Guilherme Augusto Silva dos Santos

Molecular Biology Technicians
Ana Sílvia Gouveia Lima

Andréia M Leopoldino, PhD
Depto de Análises Clínicas, Toxicológicas e Bromatológicas
Faculdade de Ciências Farmacêuticas de Ribeirão Preto Universidade de São Paulo

Dr Davide Rugero,
Associate Professor
Helen Diller Family
Cancer Research Center
University of California,
San Francisco (UCSF)
Mission Bay Campus
1450 3rd Street
Room HD 386, MC 3110
San Francisco, CA 94158
Tel: 415/514-9755
Fax: 415/514-4826
davide.ruggero@ucsf.edu

Prof. Ellen Solomon,
Prof. David Grimwade,
King’s College London
School of Medicine
Department of Medical and Molecular Medicine
Floor 8 Tower Wing
Guy’s Hospital
London SE1 9RT
Telephone : 0207 1882579
david.grimwade@genetics.kcl.ac.uk

http://www.kcl.ac.uk/medicine/research/divisions/gmm/sections/clusters/cancer/solomon/index.aspx
http://www.kcl.ac.uk/medicine/research/divisions/gmm/sections/clusters/cancer/grimwade/pgrimwade.aspx

Prof. Hau C.Kwaan,
Marjorie C. Barnett
Professor in Hematology-Oncology
Professor of Medicine
Northwestern University Feinberg School of Medicine
Room 8258, Olson Pavilion
710 N.Fairbanks Court,
Chicago, IL. 60611
h-kwaan@northwestern.edu
http://fsmweb.northwestern.edu/faculty/FacultyProfile.cfm?xid=14961

Prof. Stefan Bohlander,
Department of Medicine III,
Universität München,
81377 Munich, Germany
bohlander@helmholtz-muenchen.de
http://www.sfb684.med.uni-muenchen.de/projects/a6bohlander/index.html

Flow Cytometry and Sorting Facility,
And Small Animals Irradiator Facility,
Medical School of Ribeirão Preto,
University of São Paulo,
FAPESP EMU – grant 09/54218-1

1. Benicio MTL et al. Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience. Leuk Res. 2017; 60:109-114..
2. Corrêa de Araujo Koury L et al. Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience. Br J Haematol. 2017;177(6):979-983.
3. Bittencourt R et al. Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira – 2015. Rev Bras Hematol Hemoter. 2016; 38(1):58-74.
4. Mota JM et al. Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice. Cancer Immunol Res. 2016;4(4):312-22.
5. Lucena-Araujo AR et al. High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood. 2015; 12;126(20):2302-6.
6. Sanz MA et al. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Ann Hematol. 2015; 94(8):1347-56.
7. Rego EMet al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013; 121(11):1935-43.
8. dos Santos GA et al. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia 2012;26(3):451-60.
9. Yoon A et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science. 2006;312(5775):902-6.10. 
10. Rego EM et al. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A. 2000;97(18):10173-8.